2. Signaling Pathways
  3. Epigenetics
    Metabolic Enzyme/Protease
  4. Methionine Adenosyltransferase (MAT)

Methionine Adenosyltransferase (MAT)

S-adenosylmethionine Synthetase

Methionine adenosyltransferases (MATs), also known as S-Adenosylmethionine synthetase, are essential enzymes for life as they catalyzes the synthesis of one of the most important and pivotal biological molecules, S-adenosyl-methionine. S-adenosyl-methionine is the biological methyl donor required for a plethora of reactions within the cell.Mammalian systems express two genes, MAT1A and MAT2A, which encode for MATα1 and MATα2, the catalytic subunits of the MAT isoenzymes, respectively. A third gene MAT2B, encodes a regulatory subunit known as MATβ which controls the activity of MATα2. MAT1A, which is mainly expressed in hepatocytes, maintains the differentiated state of these cells, whilst MAT2A and MAT2B are expressed in extrahepatic tissues as well as non-parenchymal cells of the liver (e.g., hepatic stellate and Kupffer cells).

Methionine Adenosyltransferase (MAT) Related Products (12):

Cat. No. Product Name Effect Purity
  • HY-138630
    AG-270
    		99.72%
    AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM.
  • HY-107778
    PF-9366
    		99.98%
    PF-9366 is a human methionine adenosyltransferase 2A (Mat2A) inhibitor, with an IC50 of 420 nM and a Kd of 170 nM.
  • HY-112130
    AGI-24512
    		Inhibitor 99.48%
    AGI-24512 is a potent methionine adenosyltransferase 2α (MAT2A) inhibitor, with an IC50 of 8 nM. AGI-24512 triggers DNA damage response. AGI-24512 can block proliferation of MTAP-deleted cancer cells in vitro. AGI-24512 can be used for researching anticancer.
  • HY-136144
    FIDAS-5
    		98.88%
    FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities.
  • HY-139139
    MAT2A inhibitor 3
    		99.81%
    MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers.
  • HY-155149
    MAT2A-IN-12
    		Inhibitor
    MAT2A Allosteric inhibitor 2 is a potent and selective MAT2A allosteric inhibitor with an IC50 of 5 nM. MAT2A Allosteric inhibitor 2 shows nanomolar activity (IC50=5 μM) in the the proliferation assay (MTAP-/- cell line).
  • HY-149915
    MAT2A-IN-10
    		Inhibitor
    MAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC50 of 26 nM. MAT2A-IN-10 can be used for the research of cancer.
  • HY-112569
    MAT2A inhibitor 2
    		99.12%
    MAT2A inhibitor 2 is a methionine adenosyltransferase 2A (MAT2A) inhibitor.
  • HY-148499
    MAT2A-IN-9
    		Inhibitor 99.26%
    MAT2A-IN-9 (compound 167), a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenosyltransferase 2A) inhibitor.
  • HY-112131
    MAT2A inhibitor 1
    		99.57%
    MAT2A inhibitor 1 is a methionine adenosyltransferase 2A (MATA2) inhibitor with an IC50 less than l00 nM.
  • HY-139536
    MAT2A inhibitor 4
    		99.84%
    MAT2A inhibitor 4 is an inhibitor of the catalytic subunit of methionine S-adenosyltransferase-2 (MAT2A). MAT2A inhibitor 4 can be used for the research of cancer.
  • HY-112129
    AGI-25696
    AGI-25696 is a methionine adenosyltransferase 2A (MATA2 ) inhibitors useful for treatment of cancer. AGI-25696 blocks growth of MTAP-deleted tumors in vivo.